Role of the nitric oxide-cGMP pathway in the cardiovascular effects of anesthetic agents: a review.
Over the past 10 years, there has been an explosion of new information on the physiological and pathophysiological roles of nitric oxide (NO) within the cardiovascular system. With the increasing knowledge on the importance of NO in the regulation of cardiovascular function, possible involvement of the NO-cyclic guanosine-monmphosphate (cGMP) pathway in myocardial effects of anesthetics has attracted wide attention. This paper reviews the literature on the role of the nitric oxide-cGMP pathway in cardiovascular effects of volatile and intravenous anesthetics.
Lecomte
P V
PV
Department of Anesthesiology, University Hospital of Antwerp, Belgium.
De Mulder
P A
PA
Adriaensen
H F
HF
De Hert
S G
SG
D000777:Anesthetics / Q000494:pharmacology*; D000818:Animals; D006152:Cyclic GMP / Q000502:physiology*; D006321:Heart / Q000187:drug effects / Q000502:physiology*; D006801:Humans; D009200:Myocardial Contraction / Q000187:drug effects; D009569:Nitric Oxide / Q000494:pharmacology / Q000502:physiology*
D000777:Anesthetics; D009569:Nitric Oxide; D006152:Cyclic GMP